Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.38 |
| ▸ | MELK | Q14680 | 3/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19962993 | 1.00 | MAPKAPK2 (0.40) | MAPKAPK2NR3C1MELKCREBBPHTR3A | |
| SCHEMBL19962974 | 0.92 | MAPKAPK2 (0.41) | MAPKAPK2NR3C1MELKCREBBPNPY5R | |
| SCHEMBL19963019 | 0.90 | MAPKAPK2 (0.41) | MAPKAPK2NR3C1MELKCREBBPHTR3A | |
| SCHEMBL19951557 | 0.85 | MAPKAPK2 (0.55) | MAPKAPK2MELKCREBBPMAPTADORA2A | |
| SCHEMBL19962915 | 0.85 | NR3C1 (0.38) | MAPKAPK2NR3C1ADORA2AADORA2BADORA1 | |
| SCHEMBL19962989 | 0.85 | NR3C1 (0.38) | MAPKAPK2NR3C1ADORA2AADORA2BADORA1 | |
| SCHEMBL19521325 | 0.80 | MELK (0.40) | MAPKAPK2MELKCREBBPNPY5RADORA2A | |
| SCHEMBL19962886 | 0.80 | NR3C1 (0.34) | NR3C1MELKADORA2AADORA2BADORA1 | |
| SCHEMBL19962884 | 0.80 | NR3C1 (0.34) | NR3C1MELKADORA2AADORA2BADORA1 | |
| SCHEMBL19962944 | 0.80 | NR3C1 (0.34) | NR3C1MELKADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2020132700-A1 | METHODS OF USING INHIBITORS OF SREBP IN COMBINATION WITH NICLOSAMIDE AND ANALOGS THEREOF | Fgh Biotech Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018049080-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | MAPKAPK2 441/4885NR3C1 1014/4885MELK 1854/4885 |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | MAPKAPK2 441/4885NR3C1 1014/4885MELK 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.